Affordable Access

deepdyve-link
Publisher Website

18F-FDG PET/CT versus anatomic imaging for evaluating disease extent and clinical trial eligibility in Erdheim-Chester disease: results from 50 patients in a registry study.

Authors
  • Kirchner, Julian1, 2
  • Hatzoglou, Vaios1
  • Buthorn, Justin B3
  • Bossert, Dana3
  • Sigler, Allison M3
  • Reiner, Anne S4
  • Ulaner, Gary A5, 6
  • Diamond, Eli L7
  • 1 Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • 2 Department of Diagnostic and Interventional Radiology, University Dusseldorf, Medical Faculty, D-40225, Dusseldorf, Germany. , (Germany)
  • 3 Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • 4 Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, 10022, USA.
  • 5 Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. [email protected]
  • 6 Molecular Imaging and Therapy, Hoag Family Cancer Institute, Newport Beach, CA, USA. [email protected]
  • 7 Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. [email protected]
Type
Published Article
Journal
European Journal of Nuclear Medicine
Publisher
Springer-Verlag
Publication Date
Apr 01, 2021
Volume
48
Issue
4
Pages
1154–1165
Identifiers
DOI: 10.1007/s00259-020-05047-8
PMID: 33057928
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

The aim of this study was to [1] characterize distribution of Erdheim-Chester Disease (ECD) by 18F-FDG PET/CT and [2] determine the utility of metabolic (18F-FDG PET/CT) imaging versus anatomic imaging (CT or MRI) in evaluating ECD patients for clinical trial eligibility. 18F-FDG PET/CT and corresponding CT or MRI studies for ECD patients enrolled in a prospective registry study were reviewed. Sites of disease were classified as [1] detectable by 18F-FDG PET only, CT/MRI only, or both and as [2] measurable by modified PERCIST (mPERCIST) only, RECIST only, or both. Descriptive analysis was performed and paired t test for between-group comparisons. Fifty patients were included (mean age 51.5 years; range 18-70 years). Three hundred thirty-three disease sites were detected among all imaging modalities, 188 (56%) by both 18F-FDG PET and CT/MRI, 67 (20%) by 18F-FDG PET only, 75 (23%) by MRI brain only, and 3 (1%) by CT only. Of 178 disease sites measurable by mPERCIST or RECIST, 40 (22%) were measurable by both criteria, 136 (76%) by mPERCIST only, and 2 (1%) by RECIST only. On the patient level, 17 (34%) had mPERCIST and RECIST measurable disease, 30 (60%) had mPERCIST measurable disease only, and 0 had RECIST measurable disease only (p < 0.0001). Compared with anatomic imaging, 18F-FDG PET/CT augments evaluation of disease extent in ECD and increases identification of disease sites measurable by formal response criteria and therefore eligibility for clinical trials. Complementary organ-specific anatomic imaging offers the capacity to characterize sites of disease in greater anatomic detail. ClinicalTrials.gov Identifier: NCT03329274.

Report this publication

Statistics

Seen <100 times